Integrative pan-cancer landscape of MMS22L and its potential role in hepatocellular carcinoma

Integrative pan-cancer landscape of MMS22L and its potential role in hepatocellular carcinoma

Methyl methanesulfonate-sensitivity protein 22-like (MMS22L) is crucial in protecting genome integrity during DNA replication by preventing DNA damage and maintaining efficient homologous recombination. However, the role of MMS22L in human cancers remains unclear. Here, we reported the landscape of...

Full description

Bibliographic Details
Main Authors:	Zhiting Guo, Fahui Liu, Qiming Gong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Genetics
Subjects:	MMS22L pan-cancer prognosis immunotherapy hepatocellular carcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.1025970/full

Similar Items

MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma
by: Qiyu Luo, et al.
Published: (2021-09-01)

Comprehensive pan-cancer investigation of carnosine dipeptidase 1 and its prospective prognostic significance in hepatocellular carcinoma
by: Huang Xiao-Wen, et al.
Published: (2024-06-01)

A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma
by: Shenglan Huang, et al.
Published: (2022-09-01)

Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma
by: Shengyong Zhai, et al.
Published: (2024-07-01)

Corrigendum: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma
by: Shenglan Huang, et al.
Published: (2022-10-01)

The expression landscape and clinical significance of methyltransferase-like 17 in human cancer and hepatocellular carcinoma: a pan-cancer analysis using multiple databases
by: Yezhou Ding, et al.
Published: (2025-01-01)

Pan-Cancer Profiling and Digital Pathology Analysis Reveal Negative Prognostic Biomarker ZPR1 Associated with Immune Infiltration and Treatment Response in Hepatocellular Carcinoma
by: He L, et al.
Published: (2023-08-01)

Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq
by: Zhengwei Zhang, et al.
Published: (2024-05-01)

Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma
by: Zhen Wang, et al.
Published: (2022-11-01)

CAT and CXCL8 are crucial cofactors for the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma, the immune infiltration and prognosis of hepatocellular carcinoma
by: Liang Yang, et al.
Published: (2025-03-01)

The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy
by: Jiajia Du, et al.
Published: (2024-04-01)

Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma
by: Fukai Wen, et al.
Published: (2023-03-01)

Construction and experimental verification of user-friendly molecular subtypes mediated by immune-associated genes in hepatocellular carcinoma
by: Juzheng Yuan, et al.
Published: (2022-08-01)

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
by: Gok Yavuz B, et al.
Published: (2021-09-01)

Pan-cancer analysis of ARFs family and ARF5 promoted the progression of hepatocellular carcinoma
by: Qian Li, et al.
Published: (2024-04-01)

The Potential Value of RPS27A in Prognosis and Immunotherapy: From Pan-Cancer Analysis to Hepatocellular Carcinoma Validation
by: Kuai X, et al.
Published: (2024-12-01)

The Role of COL22A1 in the Pathophysiology of Hepatocellular Carcinoma: Evidence from Bioinformatics Exploration
by: Tian H, et al.
Published: (2022-02-01)

Editorial: Prognostic factors in hepatocellular carcinoma
by: Liliana Chemello, et al.
Published: (2023-11-01)

Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma
by: Jiajing Zhao, et al.
Published: (2023-12-01)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
by: Cong-Cong Wang, et al.
Published: (2023-06-01)

A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
by: Xing Fu, et al.
Published: (2022-09-01)

Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy
by: Lihua Yu, et al.
Published: (2022-07-01)

GPC-3 in hepatocellular carcinoma: current perspectives
by: Wu Y, et al.
Published: (2016-11-01)

Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates
by: Lukas Müller, et al.
Published: (2023-04-01)

Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma
by: Zhengwei Zhang, et al.
Published: (2023-05-01)

Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma
by: Jialiang Cai, et al.
Published: (2022-07-01)

The landscape in telomere related gene prognostic signature for survival and medication treatment effectiveness prediction in hepatocellular carcinoma
by: Kai Zhou, et al.
Published: (2024-12-01)

Attitude of Farmers and Scientists Towards Dissemination of Technologies Through Mobile Message Service (MMS)
by: N Shankaraiah, et al.
Published: (2015-01-01)

The combined signatures of programmed cell death and immune landscape provide a prognostic and therapeutic biomarker in the hepatocellular carcinoma
by: Wanghu Liu, et al.
Published: (2024-11-01)

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance
by: Yung-Sheng Chang, et al.
Published: (2022-02-01)

Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma
by: Sheng Wang, et al.
Published: (2023-01-01)

ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma
by: Yu Zhang, et al.
Published: (2022-07-01)

Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment
by: Xuexia Liang, et al.
Published: (2024-12-01)

Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma
by: Jianyan Pan, et al.
Published: (2025-02-01)

Constructing an immune-related prognostic signature for predicting prognosis and immune response in hepatocellular carcinoma
by: Lichao Cao, et al.
Published: (2024-07-01)

Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma
by: Han Wang, et al.
Published: (2023-05-01)

Comprehensive Analysis of Cellular Senescence-Related Genes in Prognosis, Molecular Characterization and Immunotherapy of Hepatocellular Carcinoma
by: Liang Sun, et al.
Published: (2022-12-01)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
by: Shuguang Ju, et al.
Published: (2022-03-01)

Android-Stego: A Novel Service Provider Imperceptible MMS Steganography Technique Robust to Message Loss
by: Avinash Srinivasan, et al.
Published: (2015-08-01)

Pan-cancer landscape of disulfidptosis across human tumors
by: Kun Fang, et al.
Published: (2024-11-01)